Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
147 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Dyskinesia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 13, 4, 17 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively. Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Dyskinesia - Overview 8 Dyskinesia - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 17 Dyskinesia - Therapeutics Assessment 18 Assessment by Target 18 Assessment by Mechanism of Action 21 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Dyskinesia - Companies Involved in Therapeutics Development 28 Adamas Pharmaceuticals Inc 28 Addex Therapeutics Ltd 28 Advicenne SA 29 Avanir Pharmaceuticals Inc 29 Bionomics Ltd 29 Catalyst Biosciences Inc 30 Cavion LLC 30 Clevexel Pharma SAS 31 EpiVax Inc 31 Heptares Therapeutics Ltd 31 Ipsen SA 32 Merz Pharma GmbH & Co KgaA 32 Neurim Pharmaceuticals Ltd 33 Neurocrine Biosciences Inc 33 Neurolixis Inc 33 Osmotica Pharmaceutical Corp 34 Phenomenome Discoveries Inc 34 Sage Therapeutics Inc 35 SciFluor Life Sciences LLC 35 SOM Biotech SL 35 Synchroneuron Inc 36 Dyskinesia - Drug Profiles 37 (dextromethorphan + quinidine sulfate) - Drug Profile 37 A-2M13677 - Drug Profile 42 abobotulinumtoxinA - Drug Profile 43 acamprosate calcium SR - Drug Profile 47 amantadine hydrochloride ER - Drug Profile 49 amantadine hydrochloride ER - Drug Profile 59 AT-127 - Drug Profile 60 AT-326 - Drug Profile 61 AT-403 - Drug Profile 62 befiradol - Drug Profile 63 brexanolone - Drug Profile 65 CVXL-0107 - Drug Profile 74 CX-8998 - Drug Profile 75 cycloserine - Drug Profile 76 dipraglurant IR - Drug Profile 77 Drug for Dyskinesia - Drug Profile 82 Drug for Tardive Dyskinesia - Drug Profile 83 Drugs for Dyskinesia - Drug Profile 84 Gene Therapy to Inhibit TRH for Dyskinesia - Drug Profile 85 HTL-14242 - Drug Profile 86 incobotulinumtoxin A - Drug Profile 87 IRL-790 - Drug Profile 92 JM-010 - Drug Profile 93 MLR-1019 - Drug Profile 95 NBI-640756 - Drug Profile 96 Neu-120 - Drug Profile 97 Neu-240 - Drug Profile 98 onabotulinumtoxinA - Drug Profile 99 PCT-3010 - Drug Profile 100 PPI-1011 - Drug Profile 101 RNAi Gene Therapy to Inhibit NURR1 for Dyskinesia - Drug Profile 102 SAGE-217 - Drug Profile 103 SK-609 - Drug Profile 107 Small Molecule for Dyskinesia - Drug Profile 108 Small Molecule for Dyskinesia - Drug Profile 109 Small Molecules for Neurodegenerative Disease - Drug Profile 110 Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 111 Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 112 Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 113 Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 114 Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 115 SOM-3355 - Drug Profile 116 TC-8831 - Drug Profile 117 tetrabenazine - Drug Profile 118 valbenazine tosylate - Drug Profile 119 Dyskinesia - Dormant Projects 127 Dyskinesia - Discontinued Products 129 Dyskinesia - Product Development Milestones 130 Featured News & Press Releases 130 Appendix 143 Methodology 143 Coverage 143 Secondary Research 143 Primary Research 143 Expert Panel Validation 143 Contact Us 143 Disclaimer 144
List of Tables
Number of Products under Development for Dyskinesia, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Dyskinesia - Pipeline by Adamas Pharmaceuticals Inc, H2 2017 Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2017 Dyskinesia - Pipeline by Advicenne SA, H2 2017 Dyskinesia - Pipeline by Avanir Pharmaceuticals Inc, H2 2017 Dyskinesia - Pipeline by Bionomics Ltd, H2 2017 Dyskinesia - Pipeline by Catalyst Biosciences Inc, H2 2017 Dyskinesia - Pipeline by Cavion LLC, H2 2017 Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2017 Dyskinesia - Pipeline by EpiVax Inc, H2 2017 Dyskinesia - Pipeline by Heptares Therapeutics Ltd, H2 2017 Dyskinesia - Pipeline by Ipsen SA, H2 2017 Dyskinesia - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017 Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2017 Dyskinesia - Pipeline by Neurocrine Biosciences Inc, H2 2017 Dyskinesia - Pipeline by Neurolixis Inc, H2 2017 Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp, H2 2017 Dyskinesia - Pipeline by Phenomenome Discoveries Inc, H2 2017 Dyskinesia - Pipeline by Sage Therapeutics Inc, H2 2017 Dyskinesia - Pipeline by SciFluor Life Sciences LLC, H2 2017 Dyskinesia - Pipeline by SOM Biotech SL, H2 2017 Dyskinesia - Pipeline by Synchroneuron Inc, H2 2017 Dyskinesia - Dormant Projects, H2 2017 Dyskinesia - Dormant Projects, H2 2017 (Contd..1), H2 2017 Dyskinesia - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
